|
|
Article: New ESC Heart Failure Guidelines Recommend Addition of Aldosterone Blockade Therapy to Current Standard Treatments.
- Article from:
- PR Newswire Europe
- Article date:
- May 24, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK, May 24 /PRNewswire/ --
- Pfizer's INSPRA(R) (eplerenone) has the potential to save more lives
New chronic heart failure guidelines issued by the European Society of Cardiology (ESC) recommends treatment with an aldosterone blocker to improve survival and morbidity in patients with heart failure. Aldosterone blockers are recommended for use with current standard therapy in patients with advanced heart failure (NYHA Class III or IV), or heart failure after heart attack (myocardial infarction, or MI) with left ventricular systolic dysfunction (LVSD) and signs of heart failure or diabetes. The new guidelines are based in part on the landmark ...